Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017


My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : Could Win a New Roundup Trial -- Update

share with twitter share with LinkedIn share with facebook
share via e-mail
10/10/2018 | 08:58pm EST

By Jacob Bunge

Bayer AG could win a new trial to defend its Roundup weed killer.

A California judge on Wednesday issued a tentative ruling for a new trial on the $250 million in punitive damages awarded to a groundskeeper, who sought to hold the Roundup maker liable for his non-Hodgkin lymphoma.

If finalized, Judge Suzanne Ramos Bolanos's ruling would grant a motion by Bayer arguing that sum wasn't justified and that the evidence didn't prove the company intended to harm the plaintiff. It isn't clear when the judge may finalize the ruling, issued ahead of a court hearing Wednesday.

The ruling calls into question the bulk of the $289 million judgment, the first in thousands of cases alleging that glyphosate, the main ingredient in Bayer's Roundup herbicide, causes cancer.

The jury verdict rocked Bayer weeks after the German company completed its takeover of Monsanto, the U.S. seed and pesticide giant that manufactures Roundup and crop seeds engineered to withstand the spray. Bayer's stock has fallen about 20% since the verdict, as investors priced in the potential for hundreds of millions of dollars more in court judgments ahead.

The plaintiff, Dewayne Johnson, is likely to appeal the ruling if it is finalized. Representatives for Bayer and Baum Hedlund Aristei & Goldman PC, the law firm representing Mr. Johnson, had no immediate comment.

Glyphosate is the most widely used herbicide in the world, prized for its ability to knock down scores of different weeds. Monsanto pioneered the genetic engineering of corn, soybeans and other crops to survive the chemical, helping simplify farming and turning the "Roundup Ready" franchise into a multibillion-dollar brand. Most of the nearly $11 billion in crop seeds sold annually by Monsanto are genetically modified to resist glyphosate.

The chemical's safety came under global scrutiny after the International Agency for Research on Cancer, a unit of the World Health Organization, in 2015 classified glyphosate as likely having the potential to cause cancer. Monsanto and other agricultural groups pushed back, but the classification prompted a wave of lawsuits and regulatory challenges in the U.S., Europe and elsewhere.

Mr. Johnson's attorneys, Judge Bolanos wrote in the order, didn't provide "clear and convincing evidence of malice or oppression by Monsanto."

A Bayer spokesman said the judge is considering its motions for a new trial on the liability verdicts and reduction of the $39 million in compensatory damages the jury awarded. Bayer "continues to believe that the evidence at trial does not support the verdict and the damage awards, " he said.

A Baum Hedlund spokeswoman declined to comment.

--Sara Randazzo contributed to this article.

Write to Jacob Bunge at jacob.bunge@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER
11:43aBayer gains full Vitrakvi rights from Eli Lilly's Loxo
02/12How a Philippines regulator stymied DowDuPont's global seed launch
02/11Sources Say Monsanto Wins Arbitration Ruling in India Seed Dispute -- Reuters
02/11EXCLUSIVE : Bayer's Monsanto wins arbitration ruling over royalties from Indian ..
02/08EXCLUSIVE : Brazil soy farmers say Bayer violating court ruling in patent disput..
02/07Bayer CropScience Q3 profit up over twofold
02/06BAYER : French, German farmers destroy crops after GMOs found in Bayer seeds
02/06BAYER : Return of French farmer's case keeps Monsanto in legal spotlight
02/05U.S. jury orders Takeda to pay Bayer $155 million over haemophilia drug
02/05BAYER CROPSCIENCE LIMITED : reports Q3 results
More news
Financials (€)
Sales 2018 39 254 M
EBIT 2018 7 429 M
Net income 2018 4 936 M
Debt 2018 38 407 M
Yield 2018 4,29%
P/E ratio 2018 12,21
P/E ratio 2019 14,10
EV / Sales 2018 2,54x
EV / Sales 2019 2,10x
Capitalization 61 129 M
Duration : Period :
Bayer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 90,7 €
Spread / Average Target 38%
EPS Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER8.24%69 005
JOHNSON & JOHNSON4.18%360 216
PFIZER-4.47%243 426
ROCHE HOLDING LTD.11.22%230 883
NOVARTIS6.02%225 234